Literature DB >> 33575902

[Bilateral occlusive vasculitis after intravitreal injection of brolucizumab in neovascular age-related macular degeneration].

Anna Maria Riedel1, Carlo Lackerbauer2, Chris P Lohmann3, Michael Ulbig3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33575902     DOI： 10.1007/s00347-021-01323-6

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


× No keyword cloud information.
  3 in total

1.  Fluid-based prognostication in n-AMD: Type 3 macular neovascularisation needs an analysis in isolation.

Authors:  Ashish Sharma; Nikulaa Parachuri; Nilesh Kumar; Francesco Bandello; Baruch D Kuppermann; Anat Loewenstein; Carl Regillo; Usha Chakravarthy
Journal:  Br J Ophthalmol       Date:  2020-12-08       Impact factor: 4.638

2.  HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.

Authors:  Pravin U Dugel; Rishi P Singh; Adrian Koh; Yuichiro Ogura; Georges Weissgerber; Kinfemichael Gedif; Glenn J Jaffe; Ramin Tadayoni; Ursula Schmidt-Erfurth; Frank G Holz
Journal:  Ophthalmology       Date:  2020-06-20       Impact factor: 12.079

Review 3.  Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment.

Authors:  Caroline R Baumal; Bahram Bodaghi; Michael Singer; David J Tanzer; András Seres; Mayur R Joshi; Nicolas Feltgen; Richard Gale
Journal:  Ophthalmol Retina       Date:  2020-09-29
  3 in total
  1 in total

Review 1.  A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Patient Selection, Evaluation, and Treatment.

Authors:  Frank G Holz; Tomohiro Iida; Ichiro Maruko; SriniVas R Sadda
Journal:  Retina       Date:  2022-06-13       Impact factor: 3.975
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.